Given the therapeutic potential of FGF21 analogues in metabolic disease, the selective activation of the FGF21 signalling axis in cardiomyocytes by exercise to induce SIRT3 may be an effective strategy for treating various heart diseases. This evidence concerns the gene FGF21 and metabolic disease.